stockrow
Friday 6 November 2026
Export PTCT’s income statement to Excel — free account
PTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −409.7%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
65.55
0.12
−0.18%
Follow PTCT
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| 61.08% | 20.64% | 101.97% | (104.75%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
3 | 2 | 1 | 7 | |
| (3.62%) | (1.30%) | (6.76%) | 29.66% | ||
ROIC |
17.66% | 15.16% | (6.74%) | 121.13% | |
Return on Tangible Assets |
(5.85%) | (2.02%) | (13.50%) | 50.16% | |
Average Days of Receivables |
75.20 | 86.49 | 97.05 | 38.30 | |
Free Cash Flow per Share |
(3.10) | (3.62) | (5.85) | 8.83 | |
Free Cash Flow |
(259.16) | (300.25) | (482.67) | 702.41 | |
Capital Expenditures |
(269.64) | (269.74) | (264.72) | (8.79) | |
| Other line items | |||||
Cash ROIC |
(5.42%) | (6.03%) | (11.16%) | 16.19% | |
Accounts Receivable Turnover |
5.24 | 4.64 | 3.84 | 10.18 | |
Accounts Payable Turnover |
0.21 | 0.20 | 0.20 | 0.14 | |
Inventory Turnover |
0.97 | 1.13 | 1.28 | 0.91 | |
Average Days of Payables |
2,047.99 | 1,973.96 | 1,837.65 | 2,960.12 | |
Days of Inventory on Hand |
507.95 | 471.76 | 443.59 | 618.36 | |
Tax Rate |
0.25 | (0.43) | (0.21) | (0.02) | |
Research and Development Expense of Revenue |
37.95% | 42.95% | 54.06% | 26.31% | |
Selling, General and Administrative Expense of Revenue |
29.75% | 34.47% | 42.60% | 20.06% | |
Share Based Compensation of Revenue |
7.71% | 8.39% | 9.66% | 4.31% | |
Interest Coverage |
0.74 | 0.68 | (0.35) | 5.69 | |
Operating CF/Net income |
(0.10) | 0.79 | 1.17 | 1.04 | |
Depreciation/Fixed assets |
0.89 | 0.72 | 0.55 | 0.40 | |
Capex/Depreciation |
(6.11) | (7.25) | (9.05) | (0.40) | |
Revenue per Share |
13.84 | 12.15 | 10.02 | 21.76 | |
Operating CF per Share |
0.13 | (0.37) | (2.64) | 8.94 | |
Capex per Share |
(3.23) | (3.25) | (3.21) | (0.11) | |
Capex to Sales |
0.23 | 0.27 | 0.32 | 0.01 |
Columns are period end dates · fundamentals updated 6 Nov 2026